EUCTR2011-000260-99-IE进行中（未招募）不适用
Immunogenicity of pneumococcal vaccination after prime boosting in HIV-Infected Adults: A Randomised Controlled Trial
Department of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 80 个研究点目标入组 150 人开始时间: 2011年2月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Only patients who meet all of the following inclusion criteria will be eligible for enrolment into this study:
- •1.Subjects must be HIV-1 infected adults with a CD4 cell count of >200cells/ml
- •2.Subjects must be ARV naïve or stable on antiretroviral therapy
- •3.Subjects must be free of current bacterial infection
- •4.Subjects must have no history of prior pneumococcal vaccination
- •5.Subject must be willing and able to understand and provide written, informed consent prior to participation in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant women will be excluded from the study.
- •2. Anyone who does not satisfy the above inclusion criteria will be excluded from the study.Immunotherapy
- •3. Immunization with the PPV within the past 5 years
- •4. Splenectomy
- •5. Use of intravenous immunoglobulin within the past 2 months
- •6. Chemotherapy or radiation
- •7. Any other vaccination within the past 2 months
- •8. Severe renal failure
- •9. End-stage liver disease
研究者
相似试验
招募中
不适用
De antistof respons na pneumokokkenvaccinatie bij IBD-patiënten die behandeld worden met immunosuppressiva – de PNEUMOREACT studieinflammatory bowel disease (inflammatoire darmziekte)immunosuppressive agents (immunosuppressiva)pneumococcal vaccination (pneumokokkenvaccinatie)vaccine immunogenicity (vaccin immunogeniciteit)NL-OMON29135Academic Medical Center188
进行中（未招募）
1 期
Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine. - Immunogenicity of Prevenar in Ataxia telangiectasiaEUCTR2005-004122-70-GBGreat Ormond Street Hospital30
进行中（未招募）
不适用
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly18 years old or older volunteers with general good healthEUCTR2012-003484-22-FIHelsinki University Central Hospital600
进行中（未招募）
不适用
Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantlyEUCTR2012-003484-22-SEHelsinki University Central Hospital300
已完成
不适用
Inmunogenicity-PCV-Carriage-Venezuelan High Risk ChildreInfection Prophylaxis of Streptococcus pneumoniaeRPCEC00000150Servicio Autónomo Instituto de Biomedicina110